论文部分内容阅读
《Med World News》1984;25(2):17. 美国加利福尼亚消息:在此地参加美国心脏学会(AHA)会议的研究人员预言,一种新型的血栓特异性溶解剂,即组织型血纤维蛋白溶酶原激活剂(t-PA),总有一天会由缺血性心脏病患者随身携带,自行服用。更重要的是,t-PA可经静脉给药,而且不发生与使用外源性血纤维蛋白溶酶原激活剂链激酶和尿激酶时,有关的全身性溶纤维蛋白的并发症。圣路易斯华盛顿大学心脏学主任Burton E Sobel说,如果临床试验证实t-PA安全有
Med World News 1984; 25 (2): 17. CALIFORNIA, USA: Researchers here attending the American Heart Association (AHA) predicted that a new type of thrombosis-specific lytic agent, tissue-type fibrinolysis Zymogen activator (t-PA), one day will be carried by ischemic heart disease patients, taking their own. More importantly, t-PA can be given intravenously without the complications of systemic fibrinolysis associated with the use of extrinsic plasminogen activator streptokinase and urokinase. Burton E Sobel, director of cardiology at Washington University in St. Louis, said if clinical trials confirm that t-PA is safe